Sacituzumab govitecan for HER2‑negative metastatic breast cancer in China

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicenter, open, prospective observational effort led by Zhejiang Cancer Hospital to collect real‑world efficacy and safety data on sacituzumab govitecan in HER2‑negative metastatic breast cancer. Eligible patients are adults with histologically confirmed HER2‑negative locally recurrent or metastatic disease, ECOG 0–2, measurable lesions by RECIST 1.1, life expectancy ≥12 weeks, and who have received at least two cycles of sacituzumab govitecan. The study will record tumor responses, progression measures, and treatment‑related adverse events using routine clinical assessments. Data will be used to describe outcomes in a Chinese clinical practice setting rather than to compare against a randomized control group.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Local recurrent or metastatic breast cancer suitable for chemotherapy, confirmed histologically.

HER2-negative breast cancer(according to 2018 ASCO/CAP HER2 test guideline). 18-75 years old. ECOG PS 0～2. life expectancy is not less than 12 weeks. at least one measurable lesion according to RECIST 1.1. received at least two cycles of SG. Signed informed

Exclusion Criteria:

Patients who did not receive sacituzumab govitecan treatment for two or more cycles Other malignant tumors, excluding cured cervical carcinoma in situ, skin basal cell carcinoma or skin squamous cell carcinoma, have been diagnosed in the past five years.

Female patients during pregnancy and lactation, fertile women with positive baseline pregnancy tests or women of childbearing age who are unwilling to take effective contraceptive measures throughout the trial History of neurological or psychiatric disorders Researchers believe that patients are not suitable for any other situation in this study.

Where it's running

• Zhejiang Cancer Hospital
  Hangzhou, Zhejiang, China Recruiting

Study contacts

• Principal investigator: Xiaojia Wang, MD; Ph.D — Zhejiang Cancer Hospital
• Study coordinator: Xiaojia Wang, PhD
• Email: wxiaojia0803@163.com
• Phone: 13906500190

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• First-line Sacituzumab Govitecan for Advanced Untreated Triple-Negative Breast Cancer

  This study tests whether Sacituzumab Govitecan can slow disease progression when given as a first treatment to adults with advanced triple-negative breast cancer who have not yet received treatment in the advanced setting.

  Recruiting Phase 2 British Columbia Cancer Agency · Vancouver, British Columbia · NCT07299409

• Observing the effects of Sacituzumab Govitecan in metastatic breast cancer

  This study is testing how well Sacituzumab Govitecan works and how safe it is for people with metastatic HER-2 negative breast cancer who have already tried at least two other treatments.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT06966141

• Preventing neutropenia from sacituzumab govitecan in metastatic triple-negative breast cancer

  This trial tests sacituzumab govitecan given with pegfilgrastim to see if it prevents low white blood cell counts in people with metastatic triple-negative breast cancer who have had one or two prior chemotherapy regimens.

  Recruiting Phase 2 Samsung Medical Center · Seoul · NCT06616987

• Sacituzumab Tirumotecan plus Pembrolizumab in advanced biliary tract cancer

  This study tests whether the combination of Sacituzumab Tirumotecan and Pembrolizumab can help people with advanced biliary tract cancer who have already had at least one approved therapy fail.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT07850791

• Sac-TMT and pembrolizumab with chemoradiation for bladder muscle invasion

  This trial tests whether adding Sac-TMT and pembrolizumab to chemoradiation helps people with muscle-invasive bladder cancer live longer without the cancer growing or returning.

  Recruiting at 10 sites Phase 3 Merck Sharp & Dohme LLC · Kaohsiung City and 9 other locations · NCT07829783

• Sacituzumab Govitecan plus Tislelizumab for advanced esophageal cancer

  This phase II study tests whether the cancer-fighting drug sacituzumab tirumotecan (SKB264) combined with tislelizumab can help adults with advanced esophageal squamous cell carcinoma that progressed after initial immunotherapy.

  Recruiting at 2 sites Phase 2 Shanghai Chest Hospital · Shanghai and 1 other locations · NCT07811752

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.